|
KMID : 0380020180330020070
|
|
Korean Journal of Biotechnology and Bioengineering
2018 Volume.33 No. 2 p.70 ~ p.75
|
|
|
Industrial Production of Interferon Beta for the Treatment of Multiple Sclerosis
|
|
Son Da-Jin
Kim Jong-Seok
Park Jae-Bum
Kwon Deok-Ho
Jung Hyung-Moo
Han Sang-In
Hong Eock-Kee
Ha Suk-Jin
|
|
|
Abstract
|
|
|
|
Multiple sclerosis is a chronic disorder commonly occurred in the central nervous system and is an autoimmune disease. Corticosteroids are used as a short-term treatment for multiple sclerosis, but they cause side effects. Therefore, interferon beta having antiviral and anti-inflammatory effects, is used for long-term treatment. Interferon beta-1a, produced in Chinese hamster ovary cells, is glycosylated upon biosynthesis and forms glycoform, which is similar to naturally occurring protein. However, its process has disadvantages such as slow cell growth, low yield and high contamination possibility. Also, recombinant Escherichia coli is widely used for the production of interferon beta-1b due to its rapid growth and easy process scale up, but it lacks post-translational modification, leading to low activity. In addition, the produced Interferon beta-1b might cause protein aggregation due to misfolding. Alternatively, yeast can be used as a production host possessing N-glycosylation activity. Therefore, the choice of expression system in the production of interferon beta should be carefully selected in relation to the quality and yield.
|
|
|
KEYWORD
|
|
|
multiple sclerosis, interferon beta, industrial production
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|